Three day national conference witnesses participation from over 3,500 delegates, bringing together policymakers, healthcare leaders, architects, technology experts, investors, and industry stakeholders to redefine the future of healthcare infrastructure in India The 5th Edition of the Healthcare Planning & Infrastructure Conference 2026 (HPIE 2026), organized under
New Delhi, : India and Brazil have taken a significant step towards strengthening bilateral cooperation in healthcare by signing a Memorandum of Understanding (MoU) focused on pharmaceuticals and medical product regulation. The agreement aims to enhance collaboration between regulatory authorities of both countries, fostering greater alignment
23rd October,2025, Gurugram: Artificial intelligence is increasingly making its way into healthcare as the next big force. Recognising the urgency and potential of this shift, Policybazaar for Business, the corporate arm of one of India’s largest insurance platforms, has studied its impact in its latest
Additional 75,000 Medical UG seats in next 5 years NEW DELHI, 09 October 2025: Mr JP Nadda, Minister of Health & Family Welfare, Govt of India today while addressing the ‘FICCI HEAL 2025’ said that the theme of the conference ‘Care @25 -Defining Moments in Healthcare’
“For a Viksit Bharat by 2047, India cannot limit itself to modest goals: The MedTech sector is a natural candidate for Atmanirbharata,” said Shri Piyush Goyal, Hon’ble Minister of Commerce and Industry at the 17th CII Global MedTech Summit 2025 “The theme ‘Innovating for a Healthier
The Central Drugs Standard Control Organisation (CDSCO), India's apex regulatory authority for pharmaceuticals and medical devices, has officially prohibited the import of second-hand or refurbished medical devices. This decisive action aims to safeguard patient health and bolster the domestic medical device industry. Regulatory Framework and Enforcement In
Recent studies indicate a concerning trend in India's healthcare landscape: the number of women undergoing treatment for breast cancer is projected to increase by 50,000 annually throughout this decade. This escalation is anticipated to impose an average economic burden of $19.55 billion each year. Study Insights Published
